ATE495169T1 - Toluol-solvat von darifenacin - Google Patents

Toluol-solvat von darifenacin

Info

Publication number
ATE495169T1
ATE495169T1 AT03744716T AT03744716T ATE495169T1 AT E495169 T1 ATE495169 T1 AT E495169T1 AT 03744716 T AT03744716 T AT 03744716T AT 03744716 T AT03744716 T AT 03744716T AT E495169 T1 ATE495169 T1 AT E495169T1
Authority
AT
Austria
Prior art keywords
darifenacin
toluene solvate
solvate
toluene
Prior art date
Application number
AT03744716T
Other languages
German (de)
English (en)
Inventor
Peter Dunn
John Matthews
Trevor NEWBURY
Garry O'oconnor
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE495169(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Application granted granted Critical
Publication of ATE495169T1 publication Critical patent/ATE495169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03744716T 2002-03-26 2003-03-17 Toluol-solvat von darifenacin ATE495169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207104.1A GB0207104D0 (en) 2002-03-26 2002-03-26 Stable hydrate of a muscarinic receptor antagonist
PCT/IB2003/001043 WO2003080599A1 (en) 2002-03-26 2003-03-17 Stable hydrate of a muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
ATE495169T1 true ATE495169T1 (de) 2011-01-15

Family

ID=9933731

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744716T ATE495169T1 (de) 2002-03-26 2003-03-17 Toluol-solvat von darifenacin

Country Status (22)

Country Link
US (3) US6930188B2 (enrdf_load_stackoverflow)
EP (2) EP1490357B1 (enrdf_load_stackoverflow)
JP (2) JP2005524678A (enrdf_load_stackoverflow)
KR (4) KR101026283B1 (enrdf_load_stackoverflow)
CN (1) CN100345840C (enrdf_load_stackoverflow)
AR (1) AR042608A1 (enrdf_load_stackoverflow)
AT (1) ATE495169T1 (enrdf_load_stackoverflow)
AU (1) AU2003209921A1 (enrdf_load_stackoverflow)
BR (2) BRPI0308706B8 (enrdf_load_stackoverflow)
CA (1) CA2480287C (enrdf_load_stackoverflow)
CY (2) CY1111200T1 (enrdf_load_stackoverflow)
DE (1) DE60335711D1 (enrdf_load_stackoverflow)
DK (2) DK2336124T3 (enrdf_load_stackoverflow)
ES (2) ES2394067T3 (enrdf_load_stackoverflow)
GB (1) GB0207104D0 (enrdf_load_stackoverflow)
PA (1) PA8569701A1 (enrdf_load_stackoverflow)
PT (2) PT2336124E (enrdf_load_stackoverflow)
SI (2) SI2336124T1 (enrdf_load_stackoverflow)
SV (1) SV2003001515A (enrdf_load_stackoverflow)
TW (1) TW200306816A (enrdf_load_stackoverflow)
UY (1) UY27735A1 (enrdf_load_stackoverflow)
WO (1) WO2003080599A1 (enrdf_load_stackoverflow)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
GT200600162A (es) * 2005-04-24 2007-03-14 Metodos para modular la funcion de la vejiga
CA2625858A1 (en) 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
AU2008218962B2 (en) * 2007-02-23 2013-03-14 Theravance Biopharma R&D Ip, Llc Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
US20090005309A1 (en) * 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125426A2 (en) * 2008-02-08 2009-10-15 Neuland Laboratories Ltd NOVEL PROCESS FOR THE PREPARATION OF (3SM-[2-(2 J-DIHYDRO-5- BENZOFURANYLϊETHYL]-α.α -DIPHENYL-3-PYRROLIDINEACETAMIDE HYDROBROMIDE
WO2009122997A1 (ja) 2008-04-02 2009-10-08 株式会社カネカ （ｓ）－３－（１－シアノ－１，１－ジフェニルメチル）－ピロリジンの製造法
WO2010032225A2 (en) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Process for preparation of darifenacin and intermediates used in the process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20180344735A1 (en) * 2015-12-14 2018-12-06 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
WO2018029140A1 (de) * 2016-08-12 2018-02-15 Bayer Cropscience Aktiengesellschaft Verfahren zur herstellung von substituierten styrol-derivaten
US11534589B2 (en) * 2017-09-12 2022-12-27 Lts Lohmann Therapie-Systeme Ag Iontophoretic microneedle device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9400600D0 (en) 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9612710D0 (en) * 1996-06-18 1996-08-21 Pfizer Ltd Method of treatment
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist

Also Published As

Publication number Publication date
BRPI0308706B1 (pt) 2018-07-10
BRPI0308706B8 (pt) 2021-05-25
CY1111200T1 (el) 2015-06-11
KR101026283B1 (ko) 2011-03-31
PA8569701A1 (es) 2003-12-10
GB0207104D0 (en) 2002-05-08
KR20110130539A (ko) 2011-12-05
US20050245597A1 (en) 2005-11-03
ES2394067T3 (es) 2013-01-16
US20080167367A1 (en) 2008-07-10
EP2336124B1 (en) 2012-08-29
KR20120098888A (ko) 2012-09-05
EP2336124A1 (en) 2011-06-22
JP2010195828A (ja) 2010-09-09
BR0308706A (pt) 2005-01-04
CA2480287C (en) 2011-05-31
DE60335711D1 (de) 2011-02-24
EP1490357B1 (en) 2011-01-12
HK1156626A1 (en) 2012-06-15
AR042608A1 (es) 2005-06-29
KR20100101182A (ko) 2010-09-16
BR122018000397B8 (pt) 2021-07-27
DK2336124T3 (da) 2012-12-17
CY1113433T1 (el) 2016-06-22
HK1080847A1 (zh) 2006-05-04
WO2003080599A1 (en) 2003-10-02
SI2336124T1 (sl) 2012-12-31
PT1490357E (pt) 2011-03-01
US6930188B2 (en) 2005-08-16
JP2005524678A (ja) 2005-08-18
TW200306816A (en) 2003-12-01
UY27735A1 (es) 2003-10-31
US7696357B2 (en) 2010-04-13
ES2358644T3 (es) 2011-05-12
KR20040093477A (ko) 2004-11-05
CN1642945A (zh) 2005-07-20
SI1490357T1 (sl) 2011-05-31
CA2480287A1 (en) 2003-10-02
AU2003209921A1 (en) 2003-10-08
EP1490357A1 (en) 2004-12-29
CN100345840C (zh) 2007-10-31
SV2003001515A (es) 2003-12-15
BR122018000397B1 (pt) 2019-07-02
PT2336124E (pt) 2012-12-12
KR101212908B1 (ko) 2012-12-14
US20030191176A1 (en) 2003-10-09
DK1490357T3 (da) 2011-04-04

Similar Documents

Publication Publication Date Title
DE60335711D1 (de) Toluol-Solvat von Darifenacin
FI113616B (fi) Instrumentti
EP1294378A4 (en) Thrombopoietin mimetics
NO20043696L (no) Gamma-sekretaseinhibitorer
DE60235192D1 (de) Abdeckung
ATE300197T1 (de) Handschuh
DE60321717D1 (de) Schwungrad
DE50306533D1 (de) Deckel
FR2841960B1 (fr) Bague de traversee de cloison
DE60328306D1 (de) Drucktuch
NO20043664L (no) Ny fremgangsmate
DE50313181D1 (de) Alkyl-und/oder alkylenoligoglycosid-betainesterquats
DE10393352D2 (de) Skalpell
NO20025163D0 (no) Penetrator
ITMI20021327A1 (it) Nuove ossialchilpiperazine
FI6126U1 (fi) Avoimen rakentamisen tehokas toteuttaminen
DE50300654D1 (de) Flachdichtung
DE50200691D1 (de) Spannungskomparator
UA6746S (uk) Кобза чотириструнна
NO20022407D0 (no) Sparkkoffert
SE0202929D0 (sv) Novel benzothiazepines and uses thereof
FIU20020350U0 (fi) Läpivientitiili
ITPD20020087A1 (it) Strumenti canalari
FI20020946A0 (fi) Savupelti
FR2835299B1 (fr) Support hydroelastique

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1490357

Country of ref document: EP